ClinicalTrials.gg
CompletedNCT01853800Updated Jan 23, 2017

Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet

A Phase 1 interventional study of Rivaroxaban (Xarelto, BAY59-7939) in Biological Availability, sponsored by Bayer. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-23.

Sponsored by Bayer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Rivaroxaban is a substance developed for use in the treatment of blood coagulation disorders. Thrombosis (blood clots) can occur as a result of excessive coagulation activity in the blood vessels. Excessive coagulation activity can occur in children as well, and rivaroxaban is therefore being developed for the treatment of thromboembolic events in children and adolescents. As small children are often unable to swallow tablets, an oral suspension (mixture of a liquid containing finely distributed solids) has been developed which allows dosing according to body weight. The objective of this trial is to compare the bioavailability (proportion of a substance that remains available unchanged in the blood circulation) of a rivaroxaban oral solution with that of the rivaroxaban tablet approved for treatment. In order to evaluate the potential influence of food, the oral suspension containing 20 mg rivaroxaban will be taken after consuming food. In addition, the pharmacokinetics (concentrations of the drug and breakdown products (metabolites) in blood), safety and tolerability will be assessed.

02

Conditions studied

  • Biological Availability

Keywords

  • Relative bioavailability
  • Rivaroxaban
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects
  • Age: 18 to 55 years (inclusive) at the first screening examination

Exclusion criteria

Exclusion Criteria:

  • Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
  • Known coagulation disorders (eg von Willebrand's disease, hemophilia)
  • Known disorders with increased bleeding risk (eg periodontosis, hemorrhoids, acute gastritis, peptic ulcer)
  • Known sensitivity to common causes of bleeding (eg nasal)
  • Regular use of medicines
  • findings in the (electrocardiogram) such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec or of the -interval over 450 msec
  • Clinically relevant findings in the physical examination
  • Clinically relevant deviations of the screened laboratory parameters from reference ranges
  • Participation in another clinical study during the preceding 3 months (Last Treatment from previous study to First Treatment of new study)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Rivaroxaban (Treatment A) suspension (BN03501), fasted

    Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment A, Batch number BN03501) under fasting conditions in any intervention period.

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Experimental
    Rivaroxaban (Treatment B) suspension (BN03501), fed

    Subjects received single oral dose of Rivaroxaban suspension 20 mg (Treatment B, Batch number BN03501) under fed conditions in any intervention period.

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Experimental
    Rivaroxaban (Treatment C) suspension (BR05701), fasted

    Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment C, Batch number BR05701) under fasting conditions in any intervention period.

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Experimental
    Rivaroxaban (Treatment D) IR tablet, fasted

    Subjects received single oral dose of Rivaroxaban IR tablet 10 mg (Treatment D) under fasting conditions in any intervention period.

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Versus Time Curve From Zero to Infinity After a Single Dose (AUC)

    Time frame: 0-72 hours

  2. Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose (AUC/D)

    Time frame: 0-72 hours

  3. Maximum Observed Drug Concentration in Measured Matrix After a Single Dose (Cmax)

    Time frame: 0-72 hours

  4. Maximum Observed Drug Concentration in Measured Matrix Divided by Dose (Cmax/D)

    Time frame: 0-72 hours

Secondary outcomes

  1. Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose per Kilogram Body Weight (AUC,norm)

    Time frame: 0-72 hours

  2. Area Under the Concentration Versus Time Curve From Zero to Last Quantifiable Concentration [AUC(0tlast)]

    Time frame: 0-72 hours

  3. Maximum Observed Drug Concentration Divided by Dose per Kilogram Body Weight (Cmax,norm)

    Time frame: 0-72 hours

  4. Mean Residence Time (MRT)

    Time frame: 0-72 hours

  5. Maximum Observed Drug Concentration Divided by Drug Concentration at 24 hours (Cmax/C24h)

    Time frame: 0-72 hours

  6. Time to Reach Maximum Observed Drug Concentration (tmax)

    Time frame: 0-72 hours

  7. Terminal Half Life (t1/2)

    Time frame: 0-72 hours

07

Study locations

1 site
  • Wuppertal, Nordrhein-Westfalen 42096, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Jul 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2013
First posted
May 15, 2013
Start
May 2013
Primary completionActual
Jul 2013
CompletionActual
Aug 2013
Last update
Jan 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01853800
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 15, 2013
Start date
May 2013
Primary completion
Jul 2013
Completion
Aug 2013
Last update
Jan 23, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion